SLS•benzinga•
SELLAS Life Sciences To Present Phase 2a Data On SLS009 For Relapsed/Refractory AML At ASH 2024, Showing 50% Response Rate And Median OS Of 5.5 Months At Selected Doses
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 5, 2024 by benzinga